[Comment] No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma

Long gone are the days when the challenges of conducting large phase 3 trials in patients with head and neck squamous cell carcinoma (HNSCC) seemed to stall the advancement of new therapies for this hard-to-treat cancer. Illustrative examples of practice-changing, landmark studies are the CheckMate 1411 and KEYNOTE-0482 studies, which led to the incorporation of immune checkpoint inhibitors (ICIs) in the treatment guidelines for patients with recurrent or metastatic HNSCC.